In comparison with other recent therapies for HER2-positive breast cancer, the PFS of DS-8201a for breast cancer was longer (< 10 vs. 9.9-22.1 months) [22, 26, 27, 29]. The gene discussed is ERBB2; the disease is breast cancer.